Before writing any section of a product information summary, the author must know the precise contour of the approval. The electronic package insert, the approved indications, and the approved dosage are the reference lines against which every line in the material is measured. Beyond these fixed points, post-approval evidence — RMP, early post-marketing phase vigilance, re-examination and re-evaluation, and real-world evidence — does not widen the approval; it reinforces the evidentiary foundation that the approval rests on across time. Peer-reviewed original articles underwrite the quality of that foundation.
The three pillars of the foreword — ① blocking misunderstanding, ② implementing balance on the printed page, ③ ensuring verifiability — all presuppose an accurate reproduction of the approval. Without knowing the contour of the approval, it is impossible to judge whether a given sentence blocks or creates misunderstanding. Balancing efficacy and safety information requires a grasp of both sides as the approval document presents them. And traceability to primary sources depends first on knowing which sources were consulted. Understanding these terms precedes all three pillars.
01Term reference — regulatory and approval vocabulary
Term
Meaning
Notes and implications
Electronic package insert
The primary source for proper-use information for a medicinal product. The product information summary exists to supplement it
Any discrepancy between the summary and the package insert converts supplementation into deviation. The package insert must be checked before any material is drafted
Scope of approval
The full set of indications, dosage regimens, and patient populations that a regulatory authority has authorized
One word beyond this scope is off-label — including hints and suggestions, not only direct statements
Indications and effects
The approved indication as it appears in the electronic package insert, including all qualifying wording. The full text — not the condition-free indication alone — constitutes the approved indication
The same standard applies wherever the indication is mentioned — development history, features column, anywhere
Dosage and administration
The approved route, dose, and schedule. Both the ceiling and the floor are set by the approval document
The phrase "adjust as appropriate" confers discretion within the approved range; it is not a waiver of the ceiling
Qualifying (restrictive) wording
A limiting condition attached to an indication: "only when [therapy X] is inappropriate," "patients for whom existing agents have been insufficient"
A condition, not a footnote. Drop it and the shape of the approval changes
Adjust as appropriate
A phrase in the dosage section that permits dose calibration to the patient's condition — within the upper and lower bounds specified in the approval document
Not a basis for presenting efficacy data from doses above the approved maximum
Reference information
Secondary findings obtained within the approved study: QoL, biomarker changes, exploratory subgroup results. Not primary confirmatory outcomes
Must be labeled "reference information" and kept out of the features column. Mixing it with primary endpoints invites exaggeration
RMP (risk management plan)
A post-approval framework that systematically identifies and minimizes a product's risks through safety specifications and risk minimization measures
Safety concerns identified in the RMP stand alongside package insert warnings as core safety information. No material may emphasize safety in a way that conflicts with the RMP
Early post-marketing phase vigilance
Mandatory collection of safety information from healthcare institutions during the period immediately following a new approval
The product's safety profile is still being established during this period. Statements confirming safety are especially hazardous at this stage
Re-examination / re-evaluation
Re-examination: review of a product's efficacy and safety using post-marketing use-results data. Re-evaluation: reassessment of an already-approved product against current scientific standards
While either procedure is ongoing, materials must be based on the current approved content. Anticipating outcomes not yet confirmed is impermissible
Peer-reviewed original article
A primary publication that has undergone independent critical review by subject-matter specialists before appearing in an academic journal
The highest-quality citable form for establishing verifiability. Abstracts, press releases, and conference slides are not substitutes
RWE (real-world evidence)
Knowledge derived from data generated during routine clinical care — electronic health records, registries, claims — rather than controlled trials
Carries higher bias risk than randomized controlled trials. The conditions under which RWE can support an efficacy claim are limited. RWE and RCT data must never be merged without clear differentiation
02The electronic package insert — what it means to be the primary source
The product information summary supplements the package insert; it does not precede it. The starting point for every line in any material is the package insert, and nothing may be stated in a material that the package insert does not contain.
The corollary is equally important. The risk information the package insert communicates — warnings, contraindications, serious adverse reactions — exists as a prior fact that no material can ignore. When a material selects only the safety information that favors the product, a substantive discrepancy with the package insert emerges. Recognizing the package insert as the primary source is the foundation of what the foreword calls the "asymmetric obligation" — the duty to disclose information even when it is unfavorable to the company.
03Qualifying wording — reproducing the approval means copying the condition too
Qualifying (restrictive) wording is a limiting condition attached to an indication. "Only when [treatment X] is inappropriate," "patients for whom existing therapies have proved insufficient" — these phrases are not contextual color added to the indication; they are part of the definition of the indication itself.
Dropping the condition alters the approval
What happens when an indication is written in a product information summary without its qualifying wording? The healthcare professional reading it understands that the indication may be used without restriction. What the package insert approved conditionally appears in the material as an unconditional approval. This is not a reproduction of the approved fact; it is an alteration of it.
The same standard applies in every column where the indication is mentioned — the development history column, the features column, and anywhere else. When domestic and overseas indications differ, the domestic approved content must be written separately and include the qualifying wording in full.
04Reference information — the partition from the features column must hold
Reference information consists of findings obtained incidentally within an approved study — QoL measurements, biomarker changes, exploratory subgroup analyses. These are not the confirmatory results of the primary endpoint, which is what the features column is reserved for.
Reference information must be clearly labeled as such. The features column must contain only confirmatory primary results; placing reference information there is impermissible. The features column is the section most prone to exaggeration, and when secondary findings infiltrate it, unconfirmed knowledge begins to carry the same apparent weight as the evidentiary basis for the approval. The foreword pillar of "blocking misunderstanding" is put into practice precisely by maintaining this partition.
05RWE and peer-reviewed articles — evidence quality and verifiability
Real-world evidence (RWE) is knowledge drawn from routine clinical data. Because it is not a randomized controlled trial, it inherently carries risks of selection bias, confounding, and inconsistent observation periods. Placing RWE on equal footing with RCT results is not permitted. When RWE is included in a material, the text must state that it is derived from real-world data and identify the design's limitations.
A peer-reviewed original article — whether it reports an RCT or a real-world study — is the most verifiable form of citation available. When citing, author, journal, volume, issue, and year must be given so that the reader can trace back to the primary source. This is the concrete implementation of the foreword's third pillar: verifiability. Press releases and conference slides are not acceptable substitutes.
In closing
Because the electronic package insert is the primary source, the content of any product information summary begins with the approved facts. Copy qualifying wording together with the indication. Keep reference information out of the features column. Distinguish RWE from RCT data. Present citations in a traceable form. Each of these practices is not a separate compliance exercise but a consequence of a single requirement: communicate the contour of the approval accurately so that readers can return to the primary source. The three foreword pillars all stand on an accurate understanding of the terms defined here.
Case studies — the "it isn't written, so…" mindset, and how each lands
In the approval and regulatory terminology category, the typical ploy is to reinterpret definitional boundaries in self-serving ways: "the indication name is accurate even without the qualifying condition"; "dose-above-approved-range data can be framed as reference information under 'dose adjustment as appropriate'"; "relabelling reference information lets it enter the Characteristics section." The four cases below trace that reasoning stage by stage.
GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)
The scheme: "At the top of the Characteristics section I displayed the indication name in large type and appended the qualifying condition in brackets at the end of the same line. The requirement to 'record the qualifying condition accurately together with the indication' is met — nothing is omitted, just formatted for layout purposes."
Verdict: A qualifying condition is defined as a limiting condition that forms part of the approved indication; reproducing the approval means reproducing the condition on equal terms. Setting a large indication name with a small bracketed condition shifts visual weight to the indication name and causes readers to perceive the condition as an annotation rather than a definitional constraint. The foreword's distinction between the duty not to lie and the duty not to mislead applies here: the condition may be present, but if readers do not retain "conditional approval" as the message, the reproduction fails. The qualifying condition requires legibility equal to the indication name itself.
GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)
The scheme: "The dosage section includes the phrase 'adjusted as appropriate.' I placed efficacy data from a dose above the approved ceiling in a reference-information section framed as 'data showing the effect of dose adjustment.' Since 'adjusted as appropriate' acknowledges dose variation within the approval, this data sits inside the approval, not outside it."
Verdict: The glossary explicitly defines "adjusted as appropriate" as language that permits dosing latitude within the upper and lower limits set in the approved document — not as authority to exceed the ceiling. Placing above-ceiling data in a reference-information section does not change the fact that it is off-label. Including off-label results requires a separate condition: a statement at the head of the section that part of the data is outside the approved indication, along with the reason for inclusion. Reframing above-ceiling data as in-range "dose-adjustment information" is a deliberate misuse of the definition to avoid that separate condition.
GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)
The scheme: "I placed biomarker change data — a secondary finding — in the Characteristics section under a header titled 'Pharmacological profile of this product.' Reference information cannot appear in the Characteristics section, but this is a description of pharmacological characteristics, which falls outside the definition of reference information. If the definition differs, so does the placement restriction."
Verdict: Reference information is defined by the nature of the finding — a finding obtained secondarily during the pivotal trial process that did not serve as a confirmatory primary endpoint — not by the heading under which it is presented. Relabelling biomarker change data as a "pharmacological profile" does not alter its status as a secondary finding. The PMD Act prohibits implying off-label use in a misleading manner, and the Fair Advertising Standards treat mixing reference information with primary approved data as improper advertising. Shifting the definitional frame to circumvent these higher norms is not a permissible reading strategy.
BLACK — Breaching the explicit text (a plain violation of the provision itself)
The scheme: "The indication name was too long to fit the cover layout, so I omitted the qualifying condition and recorded only the core indication name on the cover. The qualifying condition appears in full in the DI section's efficacy-and-effect entry on page 2."
Verdict: The Guidelines require that the cover record the indication accurately including associated precautionary notes, and define the qualifying condition as integral to the approved indication — not a separate annotation. The cover is the first face a reader encounters; if the qualifying condition is absent there, the product will be understood as approved for unconditional use. The DI section entry does not remedy the cover deficiency. Space constraints are a layout design problem, not grounds to omit a qualifying condition. This constitutes an alteration of approved information and requires revision.
Improper intent by implication — three scopes of "insinuating" without stating it
An approval and regulatory glossary can be written with accurate definitions and still imply meanings that soften or dilute those definitions — through a single colloquial modifier, through a sentence about regulatory trends placed immediately after a restriction, or through the sequence in which the whole glossary runs. None of the three patterns below contains a factually incorrect definition. The problem is that each definition's surrounding language steers the reader toward a less constraining reading of the rule.
Implication 1 — Local: carried in a single word or sentence
How it is built: The entry for "restrictive expression" (shibari hyōgen) defines it as: "Eligibility-limiting condition attached to an approved indication (also known as a usage restriction)."
Intent that can be read: The phrase "also known as a usage restriction" translates a legally binding condition into everyday language. The colloquial "also known as" carries a tone of familiarity — it implies that what is being described is a matter of common convention, not an immutable part of the approved indication's legal definition.
Verdict: A restrictive expression is not merely a "condition attached to" an indication; it is a constituent element of the approved indication itself. Omitting it from a material transforms the approved indication into a broader, unapproved one. The phrase "also known as a usage restriction" risks letting the reader re-read a constituent element as a contextual qualifier — something that might, in practice, be assessed by the prescriber. The correct approach is to state explicitly in the definition that omission constitutes misrepresentation of the approved scope.
Implication 2 — Adjacent: read across neighboring clauses
How it is built: "RWE (real-world evidence) inherently carries selection bias and confounding and cannot be placed on the same level as an RCT. Note that in recent years, regulatory authorities have been actively evaluating the role of post-approval RWE, and its accepted scope of use in regulatory settings is expanding." — these two sentences follow the RWE definition.
Intent that can be read: The first sentence states the limitation accurately. The sentence beginning "Note that" immediately follows with the information that regulators are actively endorsing RWE and its use is expanding. The reader is led to understand that the limitation described in the first sentence reflects a past consensus that is now changing.
Verdict: A regulatory authority's use of RWE in post-approval decisions is a distinct question from the conditions under which RWE may appear in promotional materials. Those conditions — that RWE supplements and supports the approved scope; that it must be paired with RCT data; that its design limitations must be clearly stated — have not changed. Placing "regulators are expanding RWE's role" immediately after the restriction implies that the restriction may not apply much longer, which obscures the current obligation. The correct approach is to confine regulatory trend commentary to a clearly labelled separate note and keep the restriction statement unqualified.
Implication 3 — Whole-context: arising from the document as a whole
How it is built: "The glossary is ordered: electronic package insert → prohibition on off-label statements → restrictive expressions → RWE limitations → evolving regulatory environment → peer-reviewed literature. The RWE entry closes with: 'In recent regulatory trends, post-approval RWE is increasingly expected to serve as a bridge to real-world clinical practice.' This positive statement about RWE immediately precedes the final entry, peer-reviewed literature."
Intent that can be read: Reading the glossary in sequence produces a narrative arc: from a fixed approved fact, through progressively relaxing regulatory constraints, toward a scientific ideal of peer-reviewed evidence. The RWE limitation appears not as a firm boundary but as a waypoint in a liberalising trajectory. By the end of the glossary, the cumulative impression is that approval-based restrictions are becoming less absolute.
Verdict: The function of an approval and regulatory glossary is to convey the requirements that apply to materials right now. Writing regulatory trends in affirmative terms — "increasingly expected," "expanding" — signals that current restrictions may be softened in the future and creates room for a writer to treat a present obligation as provisional. The correct approach is to separate regulatory trend commentary from the definition of current obligations, label it explicitly as informational context, and ensure that no entry implies that current requirements are subject to near-term relaxation.